Mihalache, Andrew http://orcid.org/0000-0002-2692-0759
Grad, Justin http://orcid.org/0000-0002-8048-9293
Patil, Nikhil S. http://orcid.org/0000-0003-3929-0482
Huang, Ryan S. http://orcid.org/0000-0002-3404-5376
Popovic, Marko M. http://orcid.org/0000-0002-0370-5968
Mallipatna, Ashwin
Kertes, Peter J. http://orcid.org/0000-0002-0348-5096
Muni, Rajeev H. http://orcid.org/0000-0003-0465-6472
Article History
Received: 7 August 2023
Revised: 8 March 2024
Accepted: 4 April 2024
First Online: 13 April 2024
Competing interests
: AM: None; JG: None; NSP: None; RSH: None; MMP: Financial support (to institution)—PSI Foundation, Fighting Blindness Canada; AM: None. PJK: Honoraria: Novartis, Bayer, Roche, Boehringer Ingelheim, RegenxBio, Apellis; Advisory board—Novartis, Bayer, Roche, Apellis, Novelty Nobility, Viatris, Biogen; Financial support (to institution)—Roche, Novartis, Bayer, RegenxBio; RHM: Consultant—Alcon, Apellis, AbbVie, Bayer, Bausch Health, Roche; Financial Support (to institution)- Alcon, AbbVie, Bayer, Novartis, Roche.
: An ethics statement was not required for this study type, no human or animal subjects or materials were used.